Pseudomonas aeruginosa infection
Information
- Disease name
- Pseudomonas aeruginosa infection
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04803708 | Completed | Phase 1/Phase 2 | Bacteriophage Therapy TP-102 in Diabetic Foot Ulcers | March 22, 2021 | September 5, 2022 |
| NCT01429259 | Completed | Phase 4 | Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children | February 2012 | January 2014 |
| NCT01563263 | Completed | Phase 2/Phase 3 | Confirmatory Phase II/III Study Assessing Efficacy, Immunogenicity and Safety of IC43 | March 2012 | December 2015 |
| NCT01577368 | Completed | Phase 3 | Piperacillin-Tazobactam Continuous Versus Intermittent Infusion for Pseudomonas Aeruginosa | May 2011 | August 2014 |
| NCT02421120 | Completed | Phase 4 | Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients | September 2015 | October 2016 |
| NCT01315678 | Completed | Phase 3 | Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections | February 29, 2012 | September 18, 2013 |
| NCT04636554 | No longer available | Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia | |||
| NCT06093191 | Recruiting | Phase 4 | Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis | September 25, 2023 | December 30, 2025 |
| NCT06319235 | Recruiting | Phase 1/Phase 2 | Clinical Trial to Demonstrate the Safety and Efficacy of DUOFAG® | October 27, 2023 | December 31, 2025 |
| NCT06417593 | Recruiting | Phenotypic and Genotypic Characteristics of Pseudomonas Aeruginosa Isolates in Sohag University Hospitals | April 1, 2024 | March 1, 2025 |